| Size | Price | Stock | Qty |
|---|---|---|---|
| 25U |
|
||
| 50U |
|
||
| 100U |
|
||
| 500U |
|
||
| Other Sizes |
Purity: Enzyme activity= 6.5 U/mg
| Targets |
Sialic acid substrates and glycoprotein/glycolipid acceptors. alpha-2,6-Sialyltransferase (Pd26ST) catalyzes the transfer of sialic acid from CMP-sialic acid to galactose residues of glycoproteins and glycolipids, forming α-2,6-sialyl linkages. Sialyltransferases are glycosyltransferases that play critical roles in the biosynthesis of sialylated glycoconjugates. Sialic acids on cell surfaces are involved in cellular recognition, signaling, and immune modulation. The enzyme's activity is dependent on its substrates CMP-sialic acid and appropriate acceptor molecules.
|
|---|---|
| ln Vitro |
alpha-2,6-Sialyltransferase catalyzes the transfer of sialic acid from CMP-sialic acid to galactose residues, forming α-2,6-sialyl linkages. The enzyme's activity can be measured using various acceptor substrates including glycoproteins, glycolipids, or synthetic substrates. Its specific activity depends on the substrate used and the assay conditions. The enzyme is used as a research tool for studying sialylation pathways and glycobiology.
|
| ln Vivo |
In vivo studies of alpha-2,6-sialyltransferase are primarily related to its role in glycobiology and immune function. The enzyme is involved in the biosynthesis of sialylated glycoconjugates, which play critical roles in cellular recognition, signaling, and immune modulation. Studies may focus on the regulation of sialyltransferase expression and activity in various tissues and disease states.
|
| Enzyme Assay |
Non-cell-based assays for alpha-2,6-sialyltransferase involve measuring enzyme activity using purified enzyme and substrates. The enzyme is incubated with CMP-sialic acid and an acceptor substrate (e.g., asialofetuin, or synthetic substrates). The transfer of sialic acid is measured using radiolabeled CMP-sialic acid or by detecting the formation of sialylated products by HPLC or mass spectrometry. Enzyme kinetics (Km, Vmax) can be determined by varying substrate concentrations.
|
| Cell Assay |
Cell-based assays for alpha-2,6-sialyltransferase use various cell lines to study sialylation. Cells are cultured, and the expression and activity of the enzyme are assessed by measuring cell surface sialylation using lectin binding (e.g., Sambucus nigra agglutinin, SNA) or by detecting sialylated glycoproteins by Western blot. The effects of inhibitors or modulators on sialyltransferase activity can be studied. Gene expression is analyzed by qPCR.
|
| Animal Protocol |
In vivo studies of alpha-2,6-sialyltransferase are conducted in animal models to study the role of sialylation in physiology and disease. Knockout or transgenic mouse models may be used to study the effects of altered sialyltransferase expression on development, immune function, and disease susceptibility. Tissue samples are analyzed for sialylation patterns using lectin histochemistry or mass spectrometry.
|
| ADME/Pharmacokinetics |
alpha-2,6-Sialyltransferase (Pd26ST) has a CAS number of 9075-81-4. It is a glycosyltransferase enzyme that catalyzes the formation of α-2,6-sialyl linkages. The enzyme is typically supplied as a lyophilized powder or in solution and should be stored under recommended conditions as specified by the manufacturer. It is intended for research use only.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for alpha-2,6-sialyltransferase are not applicable as the compound is an enzyme used as a research tool. Standard laboratory safety practices should be followed when handling the enzyme, including the use of personal protective equipment. It is intended for research use only.
|
| References | |
| Additional Infomation |
alpha-2,6-Sialyltransferase (Pd26ST) is an enzyme that catalyzes the transfer of sialic acid from CMP-sialic acid to galactose residues of glycoproteins and glycolipids, forming α-2,6-sialyl linkages. Sialyltransferases play critical roles in the biosynthesis of sialylated glycoconjugates, which are involved in cellular recognition, signaling, and immune modulation. The enzyme is used as a research tool for studying glycobiology, sialylation pathways, and the role of sialic acid in cell surface interactions. It is for research use only.
|
| CAS # |
9075-81-4
|
|---|---|
| Appearance |
Colorless to light yellow liquid
|
| Source |
Recombinant microorganism
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
20mM Tris-HC1 (pH8.0), 200mM NaC1, 10% glycerin.
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA